Literature DB >> 18421251

Cancer stem cells and survival pathways.

Dolores Hambardzumyan1, Oren J Becher, Eric C Holland.   

Abstract

Gliomas and medulloblastomas are the most frequent malignant brain tumors in adult and children respectively. Although both tumors arise in the CNS, there is a significant difference in their therapeutic response. Medulloblastomas are relatively curable, while glioblastomas are basically incurable. During the last decade several reports have demonstrated the existence of cancer stem cells in brain tumors, their location and their response to treatment. We have recently described the therapeutic response of medulloblastomas to radiation in their native microenvironment, illustrating how p53 and Pi3K signaling pathways lead to the evasion of cell death by the nestin-expressing cells in the perivascular stem cell niche, even while the bulk of tumor succumbs to apoptosis.(1) It remains to be determined whether this mechanism of tumor resistance applies to the more complex stem-cell niche and tumor bulk of gliomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18421251     DOI: 10.4161/cc.7.10.5954

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  50 in total

1.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.

Authors:  Sarah J Conley; Elizabeth Gheordunescu; Pramod Kakarala; Bryan Newman; Hasan Korkaya; Amber N Heath; Shawn G Clouthier; Max S Wicha
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

Review 2.  [Cancer stem cells and high-throughput screening methods].

Authors:  A Dubrovska; A Abdollahi; I Tinhofer
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

3.  Expression and function of ABCG2 and XIAP in glioblastomas.

Authors:  Ivette F Emery; Archana Gopalan; Stephanie Wood; Kin-Hoe Chow; Chiara Battelli; Joshy George; Hagen Blaszyk; Jeffrey Florman; Kyuson Yun
Journal:  J Neurooncol       Date:  2017-04-21       Impact factor: 4.130

4.  Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway.

Authors:  P-P Liu; J Liao; Z-J Tang; W-J Wu; J Yang; Z-L Zeng; Y Hu; P Wang; H-Q Ju; R-H Xu; P Huang
Journal:  Cell Death Differ       Date:  2013-10-04       Impact factor: 15.828

5.  Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.

Authors:  Tommy Alain; XueQing Lun; Yvan Martineau; Polen Sean; Bali Pulendran; Emmanuel Petroulakis; Franz J Zemp; Chantal G Lemay; Dominic Roy; John C Bell; George Thomas; Sara C Kozma; Peter A Forsyth; Mauro Costa-Mattioli; Nahum Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

Review 6.  The tumor microenvironment and its contribution to tumor evolution toward metastasis.

Authors:  Girieca Lorusso; Curzio Rüegg
Journal:  Histochem Cell Biol       Date:  2008-11-06       Impact factor: 4.304

7.  Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.

Authors:  Ryan Morrison; Stephen M Schleicher; Yunguang Sun; Kenneth J Niermann; Sungjune Kim; Daniel E Spratt; Christine H Chung; Bo Lu
Journal:  J Oncol       Date:  2010-10-12       Impact factor: 4.375

Review 8.  Brain tumor stem cells as therapeutic targets in models of glioma.

Authors:  Dan Richard Laks; Koppany Visnyei; Harley Ian Kornblum
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

Review 9.  Cancer stem cells in brain tumors and their lineage hierarchy.

Authors:  Doo-Sik Kong
Journal:  Int J Stem Cells       Date:  2012-05       Impact factor: 2.500

10.  Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB.

Authors:  Chun-Yan Li; Bao-Xiu Li; Yi Liang; Rui-Qing Peng; Ya Ding; Da-Zhi Xu; Xin Zhang; Zhi-Zhong Pan; De-Sen Wan; Yi-Xin Zeng; Xiao-Feng Zhu; Xiao-Shi Zhang
Journal:  J Transl Med       Date:  2009-07-07       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.